IGC IGC Pharma, Inc.
Financings ·
The CEO and the principal financial officer paid for the shares by cancelling amounts the company owed them, including personal cash advances. IGC Pharma paid no cash.
IGC Pharma has extended its $12,000,000 bank facility with O-Bank, and the facility fee rises from $48,000 to $60,000. The filing gives no amount drawn and no interest rate.
The notes mature in 2027 and carry 12% interest. They can convert into common stock at 75% of the lowest trading price in the prior ten trading days, and only after an event of default.
The registered direct offering is expected to bring in about $234,000 before expenses. IGC Pharma says it will use the money for working capital and general corporate purposes.
Holi Hemp LLC sold equipment, inventory and operating assets for an agreed fair value of about $2.7 million, but the consideration was supply rights and a contingent payout, with no cash. The pro forma statements show a non-cash gain of $1,051 thousand that narrows a reported quarterly loss to $548 thousand.
Holi Hemp LLC completed the disposition on September 29, 2025. IGC Pharma filed pro forma financial statements showing a $1,051 thousand gain.
IGC Pharma, Inc. set the amount under a $60,000,000 at-the-market sales agreement with A.G.P./Alliance Global Partners. The cap follows a rule that limits small companies to one-third of their public float.
IGC Pharma, Inc. is a Maryland corporation focused on Alzheimer's disease. Its lead drug candidate, IGC-AD1, is a CB1 receptor partial agonist in a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial named CALMA, which studies agitation in Alzheimer's patients. The company says IGC-AD1 has progressed through preclinical evaluations and a successful Phase 1 safety trial. Interim data from the trial show a statistically significant reduction in agitation compared to placebo within the first 2-6 weeks of treatment, and a clinical and statistically significant reduction in sleep disturbances. The company's early-stage pipeline includes preclinical candidates TGR-63, LMP, IGC-M3 and IGC-1C for Alzheimer's disease, and IGC-1A for metabolic disorders. During fiscal 2025 it reassessed its reportable segments and now operates as a single reportable segment focused on Life Sciences. The company uses artificial intelligence and machine learning models, including a tool called MINT-AD, to support early detection of Alzheimer's disease, and it reports 31 patent filings. Its fiscal year ends March 31.
| Product or program | What it is | Stage |
|---|---|---|
| IGC-AD1 | CB1 receptor partial agonist for agitation in Alzheimer's dementia | Phase 2 clinical trial (CALMA study) |
| TGR-63 | Disrupts amyloid-beta plaque formation in early to moderate Alzheimer's disease | Preclinical |
| LMP | Targets neuroinflammation, neurotransmitter imbalance and inflammasome-3 in Alzheimer's disease | Preclinical |
| IGC-M3 | Inhibits amyloid-beta plaque aggregation in early-stage Alzheimer's disease | Preclinical |
| IGC-1C | Targets tau protein phase separation; potential GLP-1 receptor agonist | Preclinical |
| IGC-1A | Potential GLP-1 and GIP receptor agonist for type 2 diabetes and obesity | Preclinical |
| Line | FY ended Mar 31, 2025 | FY ended Mar 31, 2024 |
|---|---|---|
| Revenue | $1.3 million | $1.3 million |
| Research and development | $3.7 million | $3.8 million |
| Net income (loss) | -$7.1 million | -$13.0 million |
| Cash from operations | -$4.8 million | -$5.2 million |
| Cash and equivalents | $405,000 | $1.2 million |
| Short-term investments | $0 | $0 |
Our latest story on this, dated Jan 6, 2026: "IGC Pharma agrees to sell 779,997 shares at $0.30 in direct offering". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Jul 6, 2026: "IGC Pharma issues shares to two officers at $0.27 to settle $1,154,210 owed to them". The story links the filing or release it is based on. Read the story.
IGC Pharma, Inc. trades under the ticker IGC on AMEX.
IGC Pharma, Inc. is listed on AMEX. Our directory also records these other listings: GETTEX:IGS1; LS:A1T87A; LSX:A1T87A.
The SEC Central Index Key (CIK) for IGC Pharma, Inc. is 1326205. Its filings are on SEC EDGAR.
103,384,008 shares as of 2026-08-05, per the cover page of its 10-Q filed 2026-08-14.
Our directory records IGC Pharma, Inc. under United States.
Our directory classifies IGC Pharma, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for IGC Pharma, Inc. is US45408X3089.
aibio.space lists IGC Pharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as MD.
IGC Pharma, Inc. is a Maryland corporation focused on Alzheimer's disease. Its lead drug candidate, IGC-AD1, is a CB1 receptor partial agonist in a multicenter, randomized, double-blind, placebo-controlled Phase 2 trial named CALMA, which studies agitation in Alzheimer's patients.
IGC-AD1: CB1 receptor partial agonist for agitation in Alzheimer's dementia Stage: Phase 2 clinical trial (CALMA study).
TGR-63: Disrupts amyloid-beta plaque formation in early to moderate Alzheimer's disease Stage: Preclinical.
$1.3 million for the fiscal year ended Mar 31, 2025, as reported to the SEC.
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio